共 50 条
- [31] Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358CANCER RESEARCH, 2008, 68 (09)Mita, Monica论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, San Antonio, TX USA Inst Drug Dev, San Antonio, TX USASpear, Matthew A.论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA USA Inst Drug Dev, San Antonio, TX USAYee, Lorrin K.论文数: 0 引用数: 0 h-index: 0机构: Northwest Med Specialties, Tacoma, WA USA Inst Drug Dev, San Antonio, TX USAPapadopoulos, K. P.论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, San Antonio, TX USA Inst Drug Dev, San Antonio, TX USAHeath, Elisabeth论文数: 0 引用数: 0 h-index: 0机构: Karmanos Canc Inst, Detroit, MI USA Inst Drug Dev, San Antonio, TX USARomero, Ofelia论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, San Antonio, TX USA Inst Drug Dev, San Antonio, TX USALloyd, G. Kenneth论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA USA Inst Drug Dev, San Antonio, TX USACropp, Gillian论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA USA Inst Drug Dev, San Antonio, TX USAMita, Alain论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, San Antonio, TX USA Inst Drug Dev, San Antonio, TX USALoRusso, Patricia论文数: 0 引用数: 0 h-index: 0机构: Karmanos Canc Inst, Detroit, MI USA Inst Drug Dev, San Antonio, TX USA
- [32] Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor EffectsJOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 11187 - 11213Zhu, Huajian论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaTan, Yuchen论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaHe, Chen论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaLiu, Yang论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaDuan, Yiping论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaZhu, Wenjian论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaZheng, Tiandong论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaLi, Dahong论文数: 0 引用数: 0 h-index: 0机构: Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaXu, Jinyi论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaYang, Dong-Hua论文数: 0 引用数: 0 h-index: 0机构: St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaChen, Zhe-Sheng论文数: 0 引用数: 0 h-index: 0机构: St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R ChinaXu, Shengtao论文数: 0 引用数: 0 h-index: 0机构: China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China
- [33] Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agentLEUKEMIA, 2012, 26 (08) : 1771 - 1778Benezra, M.论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USAPhillips, E.论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USATilki, D.论文数: 0 引用数: 0 h-index: 0机构: Weill Cornell Med Coll, Howard Hughes Med Inst, Ansary Stem Cell Inst, New York, NY USA Weill Cornell Med Coll, Dept Med Genet, New York, NY USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USADing, B-S论文数: 0 引用数: 0 h-index: 0机构: Weill Cornell Med Coll, Howard Hughes Med Inst, Ansary Stem Cell Inst, New York, NY USA Weill Cornell Med Coll, Dept Med Genet, New York, NY USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USAButler, J.论文数: 0 引用数: 0 h-index: 0机构: Weill Cornell Med Coll, Howard Hughes Med Inst, Ansary Stem Cell Inst, New York, NY USA Weill Cornell Med Coll, Dept Med Genet, New York, NY USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USADobrenkov, K.论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USASiim, B.论文数: 0 引用数: 0 h-index: 0机构: OXiGENE Inc, San Francisco, CA USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USAChaplin, D.论文数: 0 引用数: 0 h-index: 0机构: OXiGENE Inc, San Francisco, CA USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USARafii, S.论文数: 0 引用数: 0 h-index: 0机构: Weill Cornell Med Coll, Howard Hughes Med Inst, Ansary Stem Cell Inst, New York, NY USA Weill Cornell Med Coll, Dept Med Genet, New York, NY USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USARabbany, S.论文数: 0 引用数: 0 h-index: 0机构: Weill Cornell Med Coll, Howard Hughes Med Inst, Ansary Stem Cell Inst, New York, NY USA Weill Cornell Med Coll, Dept Med Genet, New York, NY USA Hofstra Univ, Bioengn Program, Hempstead, NY 11550 USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USABradbury, M. S.论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USA Sloan Kettering Inst Canc Res, Dept Radiol, New York, NY 10065 USA
- [34] Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agentLeukemia, 2012, 26 : 1771 - 1778M Benezra论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyE Phillips论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyD Tilki论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyB-S Ding论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyJ Butler论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyK Dobrenkov论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyB Siim论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyD Chaplin论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyS Rafii论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyS Rabbany论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of RadiologyM S Bradbury论文数: 0 引用数: 0 h-index: 0机构: Sloan Kettering Institute for Cancer Research,Department of Radiology
- [35] CHE202: A novel oral active microtubule depolymerizing vascular disrupting agent.MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)Hogberg, Marita论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, SwedenRickardson, Linda论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, SwedenDahlstedt, Emma论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, SwedenGillner, Mikael论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, SwedenJohansson, Tommy论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, SwedenRomero, Ivan论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, SwedenSmitt, Olof论文数: 0 引用数: 0 h-index: 0机构: Chemilia AB, Huddinge, Sweden Chemilia AB, Huddinge, Sweden
- [36] Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agentDRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1335 - 1351Rickardson, Linda论文数: 0 引用数: 0 h-index: 0机构: Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, Sweden Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, SwedenKutvonen, Emma论文数: 0 引用数: 0 h-index: 0机构: Univ Turku, Inst Biomed, Dept Physiol, Turku, Finland Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, SwedenOrasniemi, Satu论文数: 0 引用数: 0 h-index: 0机构: Univ Turku, Inst Biomed, Dept Physiol, Turku, Finland Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, SwedenHogberg, Marita论文数: 0 引用数: 0 h-index: 0机构: Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, Sweden Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, SwedenKallio, Marko J.论文数: 0 引用数: 0 h-index: 0机构: Univ Turku, Inst Biomed, Dept Physiol, Turku, Finland Univ Turku, Ctr Biotechnol, Turku, Finland Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, SwedenRehnmark, Stefan论文数: 0 引用数: 0 h-index: 0机构: Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, Sweden Noviga Res AB, Biovat Pk,Forskargatan 20J, S-15136 Sodertalje, Sweden
- [37] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelINVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1065 - 1073Millward, Michael论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia Univ Western Australia, Perth, WA 6009, Australia Nereus Pharmaceut Inc, San Diego, CA 92121 USAMainwaring, Paul论文数: 0 引用数: 0 h-index: 0机构: Mater Hosp, Div Canc Serv, Brisbane, Qld, Australia Nereus Pharmaceut Inc, San Diego, CA 92121 USAMita, Alain论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX USA Nereus Pharmaceut Inc, San Diego, CA 92121 USAFederico, Kristine论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA 92121 USA Nereus Pharmaceut Inc, San Diego, CA 92121 USALloyd, G. K.论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA 92121 USA Nereus Pharmaceut Inc, San Diego, CA 92121 USAReddinger, Natasha论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA 92121 USA Nereus Pharmaceut Inc, San Diego, CA 92121 USANawrocki, Steffan论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX USA Nereus Pharmaceut Inc, San Diego, CA 92121 USAMita, Monica论文数: 0 引用数: 0 h-index: 0机构: Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX USA Nereus Pharmaceut Inc, San Diego, CA 92121 USASpear, Matthew A.论文数: 0 引用数: 0 h-index: 0机构: Nereus Pharmaceut Inc, San Diego, CA 92121 USA Nereus Pharmaceut Inc, San Diego, CA 92121 USA
- [38] Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agentBRITISH JOURNAL OF CANCER, 2010, 103 (05) : 597 - 606Lickliter, J. D.论文数: 0 引用数: 0 h-index: 0机构: Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia Queensland Inst Med Res, Leukaemia Fdn Lab, Herston, Qld 4029, Australia Monash Med Ctr, Phase Canc Trials Program 1, Clayton, Vic 3168, Australia Monash Inst Med Res, Clayton, Vic 3168, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaFrancesconi, A. B.论文数: 0 引用数: 0 h-index: 0机构: Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaSmith, G.论文数: 0 引用数: 0 h-index: 0机构: Cytopia Res Pty Ltd, Richmond, Vic 3121, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaBurge, M.论文数: 0 引用数: 0 h-index: 0机构: Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia论文数: 引用数: h-index:机构:Rose, S.论文数: 0 引用数: 0 h-index: 0机构: Univ Queensland, Ctr Magnet Resonance, St Lucia, Qld 4072, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaGriffin, M.论文数: 0 引用数: 0 h-index: 0机构: Univ Queensland, Ctr Magnet Resonance, St Lucia, Qld 4072, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaMilne, R.论文数: 0 引用数: 0 h-index: 0机构: Univ S Australia, Sansom Inst, Adelaide, SA 5000, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaMcCarron, J.论文数: 0 引用数: 0 h-index: 0机构: Queensland Inst Med Res, Leukaemia Fdn Lab, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaYeadon, T.论文数: 0 引用数: 0 h-index: 0机构: Queensland Inst Med Res, Leukaemia Fdn Lab, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaWilks, A.论文数: 0 引用数: 0 h-index: 0机构: Cytopia Res Pty Ltd, Richmond, Vic 3121, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaCubitt, A.论文数: 0 引用数: 0 h-index: 0机构: Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaWyld, D. K.论文数: 0 引用数: 0 h-index: 0机构: Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, AustraliaVasey, P. A.论文数: 0 引用数: 0 h-index: 0机构: Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld 4029, Australia
- [39] Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxelJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Millward, M.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaMita, A.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaSpear, M. A.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaFederico, K. C.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaLloyd, G. K.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaCropp, G.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaMita, M.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, AustraliaMainwaring, P.论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hosp & Univ, Nedlands, WA, Australia
- [40] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelInvestigational New Drugs, 2012, 30 : 1065 - 1073Michael Millward论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyPaul Mainwaring论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyAlain Mita论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyKristine Federico论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyG. K. Lloyd论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyNatasha Reddinger论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologySteffan Nawrocki论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyMonica Mita论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical OncologyMatthew A. Spear论文数: 0 引用数: 0 h-index: 0机构: Sir Charles Gairdner Hospital & University of Western Australia,Department of Medical Oncology